SAN DIEGO, Oct. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today presented one-year data from their ongoing two-year Phase 2 clinical study of Tinlarebant in STGD1 as part of the oral presentation series at the Annual Meeting of the American Academy of Ophthalmology (AAO) held during September 30 - October 3, 2022 at McCormick Place, Chicago. 'We are glad that Tinlarebant's Phase 2 results were presented in a late-breaking oral session at the AAO annual meeting.

https://www.wallstreet-online.de/nachricht/16003986-belite-bio-presented-12-month-interim-results-of-lbs-008-phase-1b-2-study-adolescent-stargardt-disease-at-aao-annual-meeting-2022

#wallstreet-online